ArticleGynecologic oncology2023

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.

Dennis Mauricio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.